InsidersTradesSigma
Total declarations
Companies
▲ Purchases (2 ops.)
▼ Sales (0 ops.)
Insider track record
CEODisclosed buys
2
Disclosed sells
0
T+90 hit rate
0%
T+90 mean return
-24.2%
Across 1 buy signal with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Discover the full record of transactions filed by Waksal Harlan, Chairman & CEO. Insider active across 3 companies, notably Kadmon Holdings, Inc.. Cumulatively, 7 disclosures have been recorded. Breakdown: 2 buys · 0 sell. Total volume traded: €993k. History available since 13 May 2021. The latest transaction was disclosed on 18 March 2024 (Attribution). Regulator: SEC (Form 4). The full history is openly available.
Declarations7 total
275,000 shares0Common StockSEC:0000950170-24-034350:0
25,000 shares@ US$2.96387.0% of flowCommon StockSEC:0000950170-23-063137:0
Ideal exit: 6 Aug 2024 (T+270)
236,966 shares@ US$4.2274.35% mcap100.0% of flowCommon StockSEC:0000899243-22-014737:0
Ideal exit: 7 Jan 2023 (T+270)
177,945 shares@ US$9.5048.8% of flowCommon StockSEC:0001104659-21-136412:0
177,945 shares@ US$9.50100.0% of flowCommon StockSEC:0001104659-21-136412
25,000 shares@ US$3.55912.5% of flowCommon StockSEC:0001593968-21-001330:0
25,000 shares@ US$3.5591100.0% of flowCommon StockSEC:0001593968-21-001330
7 of 7 declarations
About Waksal Harlan
Harlan Waksal serves as President & CEO and Executive Chair at Kadmon Holdings, Inc. and Lyra Therapeutics, Inc. In this role, he oversees the operations and strategy of both companies. His experience in the biopharmaceutical sector allows him to make significant contributions to growth and innovation.
